Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

NCT01162122 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

7109

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)
BIOLOGICAL: Non-adjuvanted trivalent subunit influenza vaccine (TIV)

Sponsor

Novartis Vaccines